Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nicorandil
Drug ID BADD_D01562
Description Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs [T28]. Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload [A20325].
Indications and Usage Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.
Marketing Status Not Available
ATC Code C01DX16
DrugBank ID DB09220
KEGG ID D01810
MeSH ID D020108
PubChem ID 47528
TTD Drug ID D0O2SR
NDC Product Code Not Available
Synonyms Nicorandil | 2-Nicotinamidoethyl Nitrate | 2 Nicotinamidoethyl Nitrate | Nitrate, 2-Nicotinamidoethyl | 2-Nicotinamidethyl Nitrate | 2 Nicotinamidethyl Nitrate | Nitrate, 2-Nicotinamidethyl | SG-75 | SG 75 | SG75 | Ikorel | Adancor | Dancor
Chemical Information
Molecular Formula C8H9N3O4
CAS Registry Number 65141-46-0
SMILES C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal pain07.01.05.005--
Genital ulceration23.07.03.004; 21.10.05.001--Not Available
Headache17.14.01.001--
Hepatitis09.01.07.004--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Infection11.01.08.002--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Large intestinal ulcer07.04.06.004--
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.003--
Liver disorder09.01.08.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Mouth ulceration07.05.06.004--Not Available
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.011--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Peripheral vascular disorder24.03.01.003--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages